HUP0105073A2 - 2-Amino-piridin-származékok, ezek alkalmazása gyógyszerként és ezeket tartalmazó gyógyászati készítmények - Google Patents

2-Amino-piridin-származékok, ezek alkalmazása gyógyszerként és ezeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0105073A2
HUP0105073A2 HU0105073A HUP0105073A HUP0105073A2 HU P0105073 A2 HUP0105073 A2 HU P0105073A2 HU 0105073 A HU0105073 A HU 0105073A HU P0105073 A HUP0105073 A HU P0105073A HU P0105073 A2 HUP0105073 A2 HU P0105073A2
Authority
HU
Hungary
Prior art keywords
diseases
group
substituted
compounds
treatment
Prior art date
Application number
HU0105073A
Other languages
English (en)
Inventor
Serge Auvin
Dennis Bigg
Pierre-Etienne Chabrier De Lassauniere
Jerry Harnett
Dominique Pons
Gérard Ulibarri
Original Assignee
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9808732A external-priority patent/FR2780971B1/fr
Priority claimed from FR9904133A external-priority patent/FR2791674A1/fr
Application filed by Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) filed Critical Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)
Publication of HUP0105073A2 publication Critical patent/HUP0105073A2/hu
Publication of HUP0105073A3 publication Critical patent/HUP0105073A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)

Abstract

A tal lm ny az (I) ltal nos képletű vegyületekre és sóikra vonatkozik,ahol a képletben A jelentése szabadgy"k"k megk"tésére (csapd z s ra)alkalmas csoport; X jelentése t"bbnyire szubsztitu lt, főként bzisosan szubsztitu lt, 1-6 szénatomos, egyenes vagy el gazóalkilcsoport; Y jelentése adott esetben szubsztitu lt, egyenes vagy elgazó, legfeljebb 10 szénatomos (t"bbnyire b zisosan szubsztitu lt)alkil-, alkenil- vagy alkinilcsoport, vagy kén- vagy nitrogénatommalmegt"rt alkiléncsoport; R10 jelentése hidrogénatom, OH, CN, NO2 vagyszulfid-típusú csoport; vagy alkil- vagy alkoxicsoport. A tal lm nyszerinti hatóanyagok az NO-szint z enzimet g tolj k, vagy a reaktívoxigénes egységeket (ROS) megk"tik, vagy lipid peroxid ciót g tló hatssal, vagy ezen hat sok kombin ciój val rendelkeznek. Ennek alapj n atal lm ny szerinti vegyületek péld ul kardiovaszkul ris betegségek(szív- vagy agyi infarktusok), trombózisok, a k"zponti és periféri sidegrendszer megbetegedései, péld ul idegsorvad ssal j ró betegségek(Alzheimer-kór, Parkinson-betegség) kezelésében, tov bb k bítószerekmegszok s nak elh rít s ban, a v zizomzat betegségeinek, sejtburj nzssal j ró és gyullad sos megbetegedéseknek a kezelésében, szervtültetésekkel kapcsolatos sz"vődmények megszüntetésében és nagy ltalnoss gban olyan kóros llapotok kezelésében j tszhatnak szerepet,amelyekre az NO és/vagy reaktív oxigén-speciesek túlzott mennyiségűtermelődése és/vagy k ros hat sa jellemző. A tal lm ny kiterjed avegyületeket tartalmazó gyógy szati készítményekre is. Ó
HU0105073A 1998-07-08 1999-07-05 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them HUP0105073A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9808732A FR2780971B1 (fr) 1998-07-08 1998-07-08 Nouveaux derives de 2-aminopyridines, leur application en tant que medicaments et compositions pharmaceutiques les contenant
FR9904133A FR2791674A1 (fr) 1999-04-02 1999-04-02 Nouveaux derives de 2-aminopyridines, leur utilisation en tant que medicaments et compositions pharmaceutiques les contenant
PCT/FR1999/001610 WO2000002860A1 (fr) 1998-07-08 1999-07-05 Derives de 2-aminopyridines, leur utilisation en tant que medicaments et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
HUP0105073A2 true HUP0105073A2 (hu) 2002-04-29
HUP0105073A3 HUP0105073A3 (en) 2002-10-28

Family

ID=26234430

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105073A HUP0105073A3 (en) 1998-07-08 1999-07-05 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them

Country Status (19)

Country Link
US (2) US6762176B1 (hu)
EP (1) EP1095020B1 (hu)
JP (1) JP2002520317A (hu)
AR (1) AR019190A1 (hu)
AT (1) ATE303363T1 (hu)
AU (1) AU756221B2 (hu)
CA (1) CA2337258A1 (hu)
CZ (1) CZ299818B6 (hu)
DE (1) DE69927033T2 (hu)
DK (1) DK1095020T3 (hu)
ES (1) ES2249015T3 (hu)
HU (1) HUP0105073A3 (hu)
IL (2) IL140525A0 (hu)
MY (1) MY128840A (hu)
NO (1) NO318383B1 (hu)
PL (1) PL345354A1 (hu)
RU (1) RU2226527C2 (hu)
TW (1) TW509677B (hu)
WO (1) WO2000002860A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200507841A (en) * 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
US20070254055A1 (en) * 2003-11-21 2007-11-01 Trustees Of Tufts College Therapeutic Avenanthramide Compounds
US20050239892A1 (en) * 2003-11-21 2005-10-27 Trustees Of Tufts College Therapeutic avenathramide compounds
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CN103073460B (zh) * 2004-10-14 2015-09-09 Abbvie德国有限责任两合公司 适用于治疗对于多巴胺d3受体的调节有反应的疾病的芳基磺酰基甲基或芳基磺酰胺取代的芳族化合物
EP1846411A4 (en) * 2005-01-25 2010-08-04 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
BRPI0608353A2 (pt) * 2005-02-17 2009-12-01 Wyeth Corp derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilfundidos
ATE552246T1 (de) 2005-05-31 2012-04-15 Pfizer Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
US20090318290A1 (en) * 2006-07-06 2009-12-24 Bayer Cropscience Sa N-(4-pyridin-2-ylbutyl) benzamide derivatives and their use as fungicides
AU2008226947B2 (en) 2007-03-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
PL2872497T5 (pl) * 2012-07-12 2020-02-28 Khondrion Ip B.V. Pochodne chromanylowe do leczenia choroby mitochondrialnej
IN2015MN00114A (hu) 2012-07-12 2015-10-16 Khondrion Ip B V
NL2010010C2 (en) 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
ES2927699T3 (es) 2015-05-22 2022-11-10 Sulfateq Bv Compuesto para la profilaxis o el tratamiento de nefropatía diabética o enfermedad renal diabética
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
MA47305A (fr) 2017-01-11 2019-11-27 Rodin Therapeutics Inc Inhibiteurs bicycliques d'histone désacétylase
EP3664802B1 (en) 2017-08-07 2022-02-23 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
CN108558817B (zh) * 2018-03-30 2021-07-09 宁波大学 一种异香豆素类衍生物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037988A (en) * 1962-06-05 Benzoylamiivomethylpykidines
DE2830351A1 (de) 1978-07-11 1980-01-24 Consortium Elektrochem Ind Acylanilide
US4180574A (en) 1978-12-26 1979-12-25 Abbott Laboratories Certain ovicidal piperazines
US4386209A (en) * 1982-04-08 1983-05-31 Reilly Tar & Chemical Corporation Chichibabin reaction
JPS62223173A (ja) * 1986-03-25 1987-10-01 Otsuka Pharmaceut Factory Inc ピリジルアミノフエノ−ル誘導体及びその製造方法
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
WO1996018616A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
GB9506188D0 (en) 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives
CA2197364A1 (en) * 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
CN1168719C (zh) * 1996-03-29 2004-09-29 辉瑞大药厂 6-苯基吡啶-2-基胺衍生物以及药物组合物和用途
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
FR2761066B1 (fr) * 1997-03-24 2000-11-24 Sod Conseils Rech Applic Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
FR2764889B1 (fr) * 1997-06-20 2000-09-01 Sod Conseils Rech Applic Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
DE69927033D1 (de) 2005-10-06
CZ299818B6 (cs) 2008-12-03
HUP0105073A3 (en) 2002-10-28
US6762176B1 (en) 2004-07-13
JP2002520317A (ja) 2002-07-09
TW509677B (en) 2002-11-11
AU4622399A (en) 2000-02-01
EP1095020A1 (fr) 2001-05-02
MY128840A (en) 2007-02-28
CA2337258A1 (fr) 2000-01-20
US6727239B1 (en) 2004-04-27
PL345354A1 (en) 2001-12-17
NO20010031L (no) 2001-01-05
WO2000002860A1 (fr) 2000-01-20
AR019190A1 (es) 2001-12-26
RU2226527C2 (ru) 2004-04-10
DE69927033T2 (de) 2006-06-14
NO318383B1 (no) 2005-03-14
NO20010031D0 (no) 2001-01-03
IL140525A (en) 2006-08-01
EP1095020B1 (fr) 2005-08-31
CZ200186A3 (en) 2001-05-16
IL140525A0 (en) 2002-02-10
ATE303363T1 (de) 2005-09-15
ES2249015T3 (es) 2006-03-16
DK1095020T3 (da) 2006-01-16
AU756221B2 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
HUP0105073A2 (hu) 2-Amino-piridin-származékok, ezek alkalmazása gyógyszerként és ezeket tartalmazó gyógyászati készítmények
HUP9901199A2 (hu) Neurotranszmitter újrafelvételt gátló tropánszármazékok és eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
HUP0201088A2 (hu) Új alfa-aminosav-szulfonil-vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények
HUP0203965A2 (en) Indazole compounds and pharmaceutical compositions containing them
HUP0105231A2 (hu) Heteroaril-szubsztituált kinolin-2-on-származék rákellenes szerek és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
RU2203274C2 (ru) Спироциклические ингибиторы металлопротеаз
HUP0003250A1 (hu) Káliumcsatorna gátló hatású indánszármazékok és az ezeket tartalmazó gyógyszerkészítmények
HUP0401889A2 (hu) 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
HUP0303868A2 (hu) Helyettesített triazol-diamin-származékok mint kináz inhibitorok és alkalmazások gyógyszerkészítmények előállítására
BE900345A (fr) Composition pharmaceutique ophtalmiques a base d'un derive d'acide phenylacetique.
AU6279186A (en) (N-substituted-2-hydroxy) benzamides and N-substituted- 2-hydroxy-a-oxo-benzeneacetamides, pharmaceutical compositions and methods of use thereof having activity as modulators of the arachidonic acid cascade
HUP0301688A2 (hu) Aminoalkoholszármazékok, eljárás az elżállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
NO308792B1 (no) Derivater av valproinsyre og 2-valproensyreamider, farmasøytisk sammensetning derav og deres anvendelse for fremstilling av et farmasøytisk preparat
MY105402A (en) 17-beta-substituted-4-aza-5alpha-androstan-3-one derivatives and process for their preparation.
HUP0204147A2 (hu) [(RR,SS)-3-(2-dimetilaminoetil-1-hidroxiciklohexil)fenil]-2-hidroxibenzoátból származtatott új észterek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE68914292D1 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
HUP9702345A2 (hu) 3-Hidroxi-piridin-2-karbonsav-amid-észter-származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0101192A2 (hu) Cikloalkénszármazékok, előállításuk és alkalmazásuk
GEP19960656B (en) Method for production of phenylalkylamines or its pharmaceutically acceptable salts
HUP0001438A1 (hu) Új 2-(iminometil)aminofenil-származékok, előállításuk, alkalmazásuk gyógyászati készítmények előállítására, valamint az ezeket tartalmazó gyógyászati készítmények
HUP9903336A2 (hu) Szulfonsav-N-[(amino-imino-metil)-fenil]-aza-heretero-ciklil-amid származékok és az ezeket tartalmazó gyógyszerkészítmények
ATE150301T1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische zusammensetzungen davon zur prävention oder behandlung von herzerkrankungen

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees